01 1Cipla Ltd.
02 1Glaxo Wellcome Manufacturing Pte. Ltd
01 1CABOTEGRAVIR
02 1Cabotegravir
01 1India
02 1United Kingdom
NDC Package Code : 53104-7740
Start Marketing Date : 2023-11-16
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 52482-017
Start Marketing Date : 2019-12-23
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
A Cabotegravir manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cabotegravir, including repackagers and relabelers. The FDA regulates Cabotegravir manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cabotegravir API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cabotegravir manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cabotegravir supplier is an individual or a company that provides Cabotegravir active pharmaceutical ingredient (API) or Cabotegravir finished formulations upon request. The Cabotegravir suppliers may include Cabotegravir API manufacturers, exporters, distributors and traders.
click here to find a list of Cabotegravir suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cabotegravir as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Cabotegravir API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Cabotegravir as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Cabotegravir and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cabotegravir NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Cabotegravir suppliers with NDC on PharmaCompass.
LOOKING FOR A SUPPLIER?
